Featured
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting

Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting

Read More →
Immune-Onc Therapeutics Announces Positive Results from Phase 1 Dose Escalation Study of IO-108 in Advanced Solid Tumors Published in the Journal for ImmunoTherapy of Cancer

Immune-Onc Therapeutics Announces Positive Results from Phase 1 Dose Escalation Study of IO-108 in Advanced Solid Tumors Published in the Journal for ImmunoTherapy of Cancer

Read More →
Immune-Onc Therapeutics Selected for Oral Presentation at American Society of Hematology (ASH) Annual Meeting to Showcase New Data from Phase 1b Study of IO-202 in Chronic Myelomonocytic Leukemia

Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Read More →
Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Read More →
Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

Immune-Onc Announces IO-202 CMML Interim Data at EHA2024

Read More →
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by USFDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic MyelomonocyticLeukemia (CMML)

Phase 1 study of IO-202 in combination with azacitidine currently enrolling newly diagnosed CMML patients

Read More →
Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer

Collaboration to evaluate IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) as a potential first-line therapy for hepatocellular carcinoma

Read More →
Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023
Read More →
Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023
Read More →
Immune-Onc Therapeutics Announces IO-108 Phase I Clinical Trial Results Selected for Oral Presentation at AACR Annual Meeting 2023
Read More →
Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming Scientific and Investor Conferences
Read More →
Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million
Read More →
Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting
Read More →
Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors
Read More →
Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron
Read More →
Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China
Read More →
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-108 in Patients with Advanced Solid Tumors in China
Read More →
Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update
Read More →
Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors
Read More →
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
Read More →
Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer
Read More →
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
Read More →
Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting
Read More →
Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting
Read More →
Immune-Onc Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference and the Oppenheimer 32nd Annual Healthcare Conference
Read More →
Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Read More →
Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
Read More →
Immune-Onc Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Read More →
Immune-Onc Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Conference
Read More →
Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Read More →